The Business Research Company’s report on the Ischemia Reperfusion Injury Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the ischemia reperfusion injury market’s growth in recent years?
The growing prevalence of cardiovascular diseases is expected to propel the growth of the ischemia-reperfusion injury market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The growing prevalence of cardiovascular diseases is due to unhealthy lifestyle choices and an aging population. The unhealthy diets high in saturated fats, sugar, and salt, along with a lack of physical activity, led to rising rates of obesity, hypertension, and diabetes, all of which are significant risk factors for cardiovascular diseases. Ischemia-reperfusion injury contributes to the progression of cardiovascular diseases by exacerbating tissue damage through oxidative stress, inflammation, and cell death, ultimately impairing cardiac function and increasing the risk of heart failure and other complications. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, deaths due to coronary heart disease (CHD) were 14,100 in 2021 and increased to 14,900 in 2022. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the ischemia-reperfusion injury market.
Rising Incidence Of Organ Transplantation Fueling The Growth Of The Market Due To Advancements In Medical Technology And Increasing Organ Failure Rates
The rising incidence of organ transplantation is expected to propel the growth of the ischemia-reperfusion injury market going forward. Organ transplantation refers to the surgical process of transferring a healthy organ from a donor to a recipient to replace a damaged or failing organ. The rising incidence of organ transplantation is due to advancements in medical technology and the increasing number of patients with organ failure. Medical advancements in surgical techniques, immunosuppressive therapies, and organ preservation significantly improve organ transplants’ success rates. Ischemia-reperfusion injury (IRI) can be mitigated through organ transplantation by employing advanced preservation techniques that minimize the damage caused during the ischemia, ultimately improving the survival and function of the transplanted organ upon reperfusion. For instance, in January 2023, according to reports published by the United Network for Organ Sharing (UNOS), a US-based non-profit organization, in 2022, the United States saw 42,887 organ transplants, marking a 3.7% increase compared to 2021. Therefore, the rising incidence of organ transplantation is driving the growth of the ischemia-reperfusion injury market.
Access Your Free Sample of the Global Ischemia Reperfusion Injury Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22025&type=smp
How does the future projection of the ischemia reperfusion injury market size compare to its historical growth?
The ischemia reperfusion injury market size has grown strongly in recent years. It will grow from $1.56 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the rise in the prevalence of cardiovascular diseases, the increase in surgical procedures, the rise in demand for organ transplantation, the growth in the ageing population, and the increase in the incidence of stroke.
The ischemia reperfusion injury market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing demand for biomarker-based diagnostics, rising awareness about organ preservation techniques, increasing incidence of myocardial infarction, growing pharmaceutical research and development investments, and growing stem cell therapy demand. Major trends in the forecast period include technological advancements in imaging, development of novel pharmacological agents, integration of AI and machine learning in treatment, adoption of 3D printing for organ modelling, and a shift towards telemedicine.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22025&type=smp
Which key players are shaping the future of the ischemia reperfusion injury market?
Major companies operating in the ischemia reperfusion injury market are Pfizer Inc., Prolong Pharmaceuticals LLC, BMG LABTECH GmbH, Domainex Ltd, CFM Pharma Holding BV, Simcere Innovation Inc., Larix Bioscience LLC, Faron Pharmaceuticals Oy, LUCA Science Inc., Faraday Pharmaceuticals Inc., Athersys Inc., Alloksys Life Sciences B.V., Ischemix Inc., New Horizons Pharma Inc., Oxitope Pharma BV, PharmaTher Holdings Ltd, Revive Therapeutics Ltd, Corline Biomedical AB, Angion Biomedica Corp., Radikal Therapeutics Inc.
What trends will propel the growth and evolution of the ischemia reperfusion injury market?
Major companies operating in the ischemia-reperfusion injury market are focusing on developing innovative treatments, such as ketamine-based treatments, to reduce tissue damage and inflammation associated with ischemia-reperfusion injury. Ketamine-based treatments refer to medical therapies that use ketamine, a dissociative anesthetic, for various health conditions. These treatments are used mainly for mental health disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD), as well as for pain management. For instance, in December 2022, PharmaTher Holdings Ltd., a Canada-based pharmaceutical company, received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for ketamine to prevent ischemia-reperfusion injury from organ transplantation. This drug lessens the injury from ischemia-reperfusion by inhibiting NF-?B, thereby suppressing the production of proinflammatory cytokines such as IL-6 and TNF-a. It also exhibits anti-inflammatory effects by inhibiting leukocyte reactivity, which helps reduce immune-mediated damage to transplanted organs.
Which regions are expected to become dominant players in the ischemia reperfusion injury market?
North America was the largest region in the ischemia reperfusion injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemia reperfusion injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/ischemia-reperfusion-injury-global-market-report
What are the emerging key segments in the ischemia reperfusion injury market, and how are they evolving?
The ischemia reperfusion injury market covered in this report is segmented –
1) By Treatment Type: Pharmacological Therapy, Non-pharmacological Therapy
2) By Application: Cardiovascular Diseases, Stroke, Organ Transplantation, Heart Attack, Diabetes
3) By End Users: Hospitals, Clinics, Ambulatory Services, Nursing Home
Subsegments:
1) By Pharmacological Therapy: Antioxidants, Anti-inflammatory Agents, Calcium Channel Blockers, Free Radical Scavengers, Nitric Oxide Donors, Mitochondrial Protective Agents.
2) By Non-Pharmacological Therapy: Ischemic Preconditioning (IPC), Ischemic Postconditioning (IPO), Remote Ischemic Conditioning (RIC), Hypothermia Therapy, Mechanical Interventions, Gene and Stem Cell Therapy.
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22025
What defines the structure and scope of the ischemia reperfusion injury market?
Ischemia-reperfusion injury is the tissue damage that occurs when blood supply returns to tissue after a period of ischemia (lack of oxygen). The restoration of circulation can result in inflammation and oxidative damage. This injury involves pathophysiological mechanisms with local and systemic effects.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
